نتائج البحث - MacPartlin, Mary
- يعرض 1 - 5 نتائج من 5
-
1
-
2
-
3
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL(T315I) and exhibits a narrow resistance profile حسب Eide, Christopher A., Adrian, Lauren T., Tyner, Jeffrey W., Mac Partlin, Mary, Anderson, David J., Wise, Scott C., Smith, Bryan, Petillo, Peter A., Flynn, Daniel L., Deininger, Michael W.N., O’Hare, Thomas, Druker, Brian J.
منشور في 2011نص -
4
Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib حسب Griswold, Ian J., MacPartlin, Mary, Bumm, Thomas, Goss, Valerie L., O'Hare, Thomas, Lee, Kimberly A., Corbin, Amie S., Stoffregen, Eric P., Smith, Caitlyn, Johnson, Kara, Moseson, Erika M., Wood, Lisa J., Polakiewicz, Roberto D., Druker, Brian J., Deininger, Michael W.
منشور في 2006نص -
5
A gene expression signature of CD34(+) cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib حسب McWeeney, Shannon K., Pemberton, Lucy C., Loriaux, Marc M., Vartanian, Kristina, Willis, Stephanie G., Yochum, Gregory, Wilmot, Beth, Turpaz, Yaron, Pillai, Raji, Druker, Brian J., Snead, Jennifer L., MacPartlin, Mary, O'Brien, Stephen G., Melo, Junia V., Lange, Thoralf, Harrington, Christina A., Deininger, Michael W. N.
منشور في 2010نص